Corindus Vascular Robotics Inc (NYSEMKT:CVRS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The firm presently has a $1.75 price objective on the medical equipment provider’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 10.76% from the company’s previous close.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Several other equities analysts have also commented on the company. ValuEngine raised Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. BidaskClub lowered Corindus Vascular Robotics from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Finally, Cowen and Company set a $3.00 target price on Corindus Vascular Robotics and gave the company a “buy” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $2.58.

Corindus Vascular Robotics (NYSEMKT:CVRS) traded up 3.27% on Friday, reaching $1.58. The company had a trading volume of 1,664,821 shares. The stock has a 50 day moving average of $1.67 and a 200 day moving average of $1.45. Corindus Vascular Robotics has a 12 month low of $0.40 and a 12 month high of $2.25. The firm’s market capitalization is $295.93 million.

Corindus Vascular Robotics (NYSEMKT:CVRS) last announced its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $2.26 million during the quarter, compared to analyst estimates of $3.10 million. Corindus Vascular Robotics had a negative return on equity of 94.27% and a negative net margin of 372.63%. On average, analysts anticipate that Corindus Vascular Robotics will post ($0.21) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Corindus Vascular Robotics Inc (CVRS) Lifted to “Buy” at Zacks Investment Research” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/15/corindus-vascular-robotics-inc-cvrs-lifted-to-buy-at-zacks-investment-research.html.

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its holdings in Corindus Vascular Robotics by 147.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock worth $109,000 after buying an additional 35,086 shares in the last quarter. Rhumbline Advisers grew its holdings in Corindus Vascular Robotics by 67.6% in the 2nd quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock worth $150,000 after buying an additional 32,608 shares in the last quarter. New York State Common Retirement Fund grew its holdings in Corindus Vascular Robotics by 334.6% in the 2nd quarter. New York State Common Retirement Fund now owns 89,100 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 68,599 shares in the last quarter. California State Teachers Retirement System grew its holdings in Corindus Vascular Robotics by 34.4% in the 2nd quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock worth $276,000 after buying an additional 38,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Corindus Vascular Robotics by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock worth $214,000 after buying an additional 9,684 shares in the last quarter.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.